Funds holding Erasca Inc
ISIN US29479A1088 · United States
- Fund holders
- 215
- Of which ETFs
- 40 175 other funds
- Value held
- 964.6M $
- Share of capital
- 18.3 % of 349.8M shares on Aug 4, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| SA Franklin Tactical Opportunities Portfolio SUNAMERICA SERIES TRUST | 836 | 8.9K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Innovator U.S. Small Cap Managed 10 Buffer ETF Innovator ETFs Trust | 665 | 7.1K $ | 0.09 % | 0.00 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Innovation Leaders ETF T. Rowe Price Exchange-Traded Funds, Inc. | 661 | 10.7K $ | 0.07 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 634 | 10.3K $ | 0.07 % | 0.00 % | as of Mar 31, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 506 | 5.4K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 479 | 7.8K $ | 0.07 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 407 | 6.6K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 346 | 3.7K $ | 0.05 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Gotham Enhanced Return Fund FundVantage Trust | 263 | 4.3K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 256 | 4.1K $ | 0.07 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 178 | 2.4K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 161 | 2.6K $ | 0.09 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs MSCI World Private Equity Return Tracker ETF Goldman Sachs ETF Trust | 76 | 1K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 56 | 765 $ | 0.07 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 46 | 744.3 $ | 0.03 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 2.19 % | as of Apr 30, 2026 ↗ |
| Invesco Dorsey Wright Healthcare Momentum ETF Invesco Exchange-Traded Fund Trust | 1.71 % | as of Apr 30, 2026 ↗ |
| Tema Oncology ETF Tema ETF Trust | 1.45 % | as of Feb 28, 2026 ↗ |
| Victory Pioneer Select Mid Cap Growth VCT Portfolio Victory Variable Insurance Funds II | 1.37 % | as of Mar 31, 2026 ↗ |
| Victory Pioneer Select Mid Cap Growth Fund Victory Portfolios IV | 1.09 % | as of Feb 28, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.03 % | as of Mar 31, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 1.00 % | as of Mar 31, 2026 ↗ |
| ALGER SMALL CAP FOCUS FUND ALGER FUNDS | 0.81 % | as of Apr 30, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 0.64 % | as of Mar 31, 2026 ↗ |
| ALGER HEALTH SCIENCES FUND ALGER FUNDS | 0.59 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 215 | +81 | 64,023,533 | +49.8 % |
| 2026Q1 | 134 | +11 | 42,737,017 | -0.1 % |
| 2025Q4 | 123 | -4 | 42,785,336 | -3.0 % |
| 2025Q3 | 127 | -8 | 44,124,035 | +2.0 % |
| 2025Q2 | 135 | -6 | 43,252,033 | -4.6 % |
| 2025Q1 | 141 | -5 | 45,346,255 | -0.7 % |
| 2024Q4 | 146 | +12 | 45,674,606 | +68.3 % |
| 2024Q3 | 134 | +20 | 27,143,151 | +110.2 % |
| 2024Q2 | 114 | -8 | 12,910,047 | -0.6 % |
| 2024Q1 | 122 | -6 | 12,988,005 | -5.7 % |
| 2023Q4 | 128 | 13,776,862 |
Institutional managers
216 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24,675,188 | 399.2M $ | as of Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 21,259,646 | 344K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 20,151,406 | 326M $ | as of Mar 31, 2026 |
| Venrock Adviser, LLC | 16,382,812 | 265.1M $ | as of Mar 31, 2026 |
| RTW INVESTMENTS, LP | 16,157,175 | 261.4M $ | as of Mar 31, 2026 |
| Vivo Capital, LLC | 12,151,480 | 196.6M $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 11,244,246 | 181.9M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 11,150,000 | 180.4M $ | as of Mar 31, 2026 |
| Paradigm Biocapital Advisors LP | 10,392,702 | 168.2M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 9,300,084 | 150.5M $ | as of Mar 31, 2026 |
| ARCH Venture Management, LLC | 7,091,557 | 114.7M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 5,996,149 | 97M $ | as of Mar 31, 2026 |
| Cormorant Asset Management, LP | 5,800,000 | 93.8M $ | as of Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 5,350,000 | 86.6M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 5,143,985 | 83.2M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 4,875,186 | 78.9M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 3,710,966 | 60M $ | as of Mar 31, 2026 |
| 5AM Venture Management, LLC | 3,485,971 | 56.4M $ | as of Mar 31, 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,434,967 | 55.6M $ | as of Mar 31, 2026 |
| Commodore Capital LP | 3,175,000 | 51.4M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 3,055,897 | 49.4M $ | as of Mar 31, 2026 |
| a16z Capital Management, L.L.C. | 2,862,500 | 46.3M $ | as of Mar 31, 2026 |
| Woodline Partners LP | 2,831,538 | 45.8M $ | as of Mar 31, 2026 |
| ALLIANCEBERNSTEIN L.P. | 2,644,920 | 9.8M $ | as of Mar 31, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,100,000 | 34M $ | as of Mar 31, 2026 |
Declared shareholders of Erasca Inc
There are 5 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 6.80 % | 21,224,264 | as of Mar 31, 2026 · SCHEDULE 13G |
| Venrock Healthcare Capital Partners III, L.P. and 6 others | 5.30 % | 16,382,812 | as of Mar 31, 2026 · SCHEDULE 13G |
| RTW Investments, LP and 1 other | 5.20 % | 16,157,175 | as of Mar 31, 2026 · SCHEDULE 13G |
| Paradigm BioCapital Advisors LP and 3 others | 3.30 % | 10,392,702 | as of Mar 31, 2026 · SCHEDULE 13G |
| Suvretta Capital Management, LLC and 2 others | 1.10 % | 3,434,967 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Erasca Inc". https://titelia.com/en/stocks/erasca-inc-US29479A1088